1. Home
  2. JBI vs ANNX Comparison

JBI vs ANNX Comparison

Compare JBI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janus International Group Inc.

JBI

Janus International Group Inc.

HOLD

Current Price

$5.02

Market Cap

987.0M

Sector

Industrials

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.40

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBI
ANNX
Founded
2002
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
987.0M
972.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
JBI
ANNX
Price
$5.02
$5.40
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
$9.17
$16.50
AVG Volume (30 Days)
1.6M
2.0M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.36
N/A
Revenue Next Year
$3.16
$16,320.74
P/E Ratio
$12.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.26
$1.85
52 Week High
$10.80
$7.18

Technical Indicators

Market Signals
Indicator
JBI
ANNX
Relative Strength Index (RSI) 42.37 39.87
Support Level $4.86 $4.79
Resistance Level $5.57 $5.61
Average True Range (ATR) 0.25 0.28
MACD -0.01 -0.07
Stochastic Oscillator 58.40 12.76

Price Performance

Historical Comparison
JBI
ANNX

About JBI Janus International Group Inc.

Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: